Brain-Spray chemo cocktail targets breast Cancer's deadliest spread
NCT ID NCT06543992
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This phase II trial tests whether injecting two chemotherapy drugs—thiotepa and methotrexate—directly into the spinal fluid can shrink or control breast cancer that has spread to the leptomeninges (the lining of the brain and spinal cord). Participants receive the drugs through an implanted Ommaya reservoir, a device that allows repeated access to the spinal fluid. The study will measure how many patients respond and how long the response lasts, while monitoring safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of thiotepa and methotrexate given directly into the spinal fluid via an Ommaya reservoir
- What this could lead to
- If successful, this could offer a new treatment option for breast cancer that has spread to the lining of the brain and spinal cord, potentially improving response rates and delaying disease progression.
- What could go wrong
- This is a small, early-phase trial with only 22 participants, so results may not apply broadly. The treatment involves direct injection into the spinal fluid, which carries risks like infection, nerve damage, or side effects from the chemotherapy drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASIS OF BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Provincial People's Hospital
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.